Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 172
News
News | 02 December 2021

ZyCoV-D to be initially administered in seven states

The three doses of ZyCoV-D are to be administered 28 days apart. The vaccine was given emergency use authorisation (EUA) by the Indian drug regulator on August 20

News
News | 30 November 2021

DaVita research indicates effectiveness of mRNA vaccine in dialysis patients

Researchers observed that the Pfizer/BioNTech and Moderna vaccines were 78% and 73% effective in preventing Covid-19 infections, respectively

News
News | 30 November 2021

Conference highlights opportunities in the nursing profession

This collaborative nursing conference generated a positive dialogue on how the healthcare space of nursing has evolved in the past year

News
News | 30 November 2021

Lupin launches learning platform for medical students

Sciflix is a special Initiative by Lupin to assist future pulmonologists in staying abreast of the latest medical advances relevant to their speciality

News
News | 30 November 2021

RDIF believes that Sputnik vaccines can neutralise Omicron

According to the Russian Direct Investment Fund (RDIF), the Russian Sputnik V and Sputnik Light vaccines have proven to be highly effective against all variants of SARC-Cov-2

News
News | 30 November 2021

UAE authorises Sputnik Light vaccine as universal booster

Booster dose is available to all residents aged 18+ and can be applied six months after the second dose of any other vaccine administered in UAE

News
News | 29 November 2021

Bharat Biotech commences export of Covaxin

It’s a two-dose vaccine administered 28 days apart

News
News | 27 November 2021

Fifty-five manufacturers selected for Pharma PLI sector

The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme

News
News | 26 November 2021

Indian Pharmaceutical Market reports slower growth in October

Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins

News
News | 25 November 2021

NFHS-5 shows momentum towards achieving SDG

The main objective of successive rounds of the NFHS is to provide reliable and comparable data relating to health and family welfare and other emerging issues

News
News | 25 November 2021

Sputnik Light in India by December: RDIF

One-shot Sputnik Light is a highly effective vaccine when used both on standalone basis and applied as a booster

News
News | 25 November 2021

Cadila partners with Enzychem of South Korea to manufacture ZyCoV-D

The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022

News
News | 25 November 2021

Bharat Biotech updates on the Lancet study on Covaxin efficacy

An effectiveness result of 50 per cent achieved during the peak delta variant Covid-19 wave in India, in a highrisk study population of physicians and healthcare workers, in a hospital environment, provides insights into the efficacy and effectiveness of Covaxin

News
News | 25 November 2021

Air pollution reduces life expectancy by eight years in India

India registers 18% of deaths annually due to air pollution while seven million die annually across the world due to air pollution

News
News | 25 November 2021

ADB approves US $ 1.5 bn for Covid-19 vaccines in India

The loan will fund at least 667 million Covid-19 vaccine doses for an estimated 317 million people

News
News | 24 November 2021

ACG to set up Asia's largest capsule plant in Maharashtra

Officials from ACG signed the MoU with the Maharashtra government for the Rs 600 crore investment in the backward region of Marathwada

News
News | 24 November 2021

Ipca Laboratories acquires 26 % stake in Lyka Labs, makes open offer

For the six months ended September 30, 2021, Lyka had reported revenues of Rs 109.87 crore

News
News | 23 November 2021

Indian pharma CEOs bet big on innovation to achieve US $130 bn

While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation

News
News | 22 November 2021

Merck showcases potential for several cancers, MS and lupus

Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline

News
News | 20 November 2021

Funding push to pharma R&D critical for unleashing next phase of growth

The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation

Startup

Digitization